Sands Capital Management Cut By $71.41 Million Its Regeneron Pharmaceuticals (REGN) Stake; Shorts at Yamana Gold (AUY) Lowered By 38.24%

September 7, 2017 - By Vivian Park

Yamana Gold Incorporated (NYSE:AUY) had a decrease of 38.24% in short interest. AUY’s SI was 19.41M shares in September as released by FINRA. Its down 38.24% from 31.43 million shares previously. With 11.54 million avg volume, 2 days are for Yamana Gold Incorporated (NYSE:AUY)’s short sellers to cover AUY’s short positions. About 1.49 million shares traded. Yamana Gold Inc. (USA) (NYSE:AUY) has declined 40.97% since September 7, 2016 and is downtrending. It has underperformed by 57.67% the S&P500.

Sands Capital Management Llc decreased Regeneron Pharmaceuticals (REGN) stake by 7.79% reported in 2016Q4 SEC filing. Sands Capital Management Llc sold 194,576 shares as Regeneron Pharmaceuticals (REGN)’s stock rose 21.24%. The Sands Capital Management Llc holds 2.30M shares with $845.34 million value, down from 2.50M last quarter. Regeneron Pharmaceuticals now has $50.65B valuation. The stock declined 5.51% or $27.57 reaching $472.65 per share. About 456,274 shares traded. Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has risen 17.40% since September 7, 2016 and is uptrending. It has outperformed by 0.70% the S&P500.

Among 12 analysts covering Yamana Gold Inc. (NYSE:AUY), 3 have Buy rating, 1 Sell and 8 Hold. Therefore 25% are positive. Yamana Gold Inc. had 33 analyst reports since July 22, 2015 according to SRatingsIntel. As per Monday, June 12, the company rating was maintained by RBC Capital Markets. JP Morgan initiated Yamana Gold Inc. (USA) (NYSE:AUY) on Friday, December 11 with “Overweight” rating. The company was maintained on Tuesday, June 20 by BMO Capital Markets. The stock has “Buy” rating by HSBC on Wednesday, July 22. The company was maintained on Tuesday, July 18 by RBC Capital Markets. HSBC downgraded Yamana Gold Inc. (USA) (NYSE:AUY) on Monday, October 26 to “Hold” rating. The firm has “Mkt Perform” rating by Raymond James given on Friday, January 15. The firm has “Outperform” rating given on Thursday, May 12 by BMO Capital Markets. The rating was downgraded by Goldman Sachs on Wednesday, February 24 to “Sell”. The company was maintained on Wednesday, August 9 by RBC Capital Markets.

Yamana Gold Inc. is a gold producer with gold production, gold development stage properties, exploration properties, and land positions throughout the Americas, including Canada, Brazil, Chile and Argentina. The company has market cap of $2.86 billion. The Company’s divisions include Chapada mine in Brazil; El Penon mine in Chile; Canadian Malartic mine in Canada; Gualcamayo mine in Argentina; Minera Florida mine in Chile; Jacobina mine in Brazil; Brio Gold Inc. , and Corporate and other. It currently has negative earnings. The Company’s development projects include Cerro Moro, Argentina; Agua Rica, Argentina, and Gualcamayo, Argentina.

Among 28 analysts covering Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), 14 have Buy rating, 1 Sell and 13 Hold. Therefore 50% are positive. Regeneron Pharmaceuticals Inc. had 78 analyst reports since July 28, 2015 according to SRatingsIntel. BMO Capital Markets maintained Regeneron Pharmaceuticals Inc (NASDAQ:REGN) rating on Thursday, August 3. BMO Capital Markets has “Hold” rating and $49100 target. Leerink Swann maintained the shares of REGN in report on Monday, August 3 with “Outperform” rating. The firm earned “Sell” rating on Monday, November 7 by Chardan Capital Markets. Chardan Capital Markets maintained Regeneron Pharmaceuticals Inc (NASDAQ:REGN) rating on Friday, January 6. Chardan Capital Markets has “Neutral” rating and $345 target. The firm has “Hold” rating given on Monday, September 4 by Jefferies. The firm has “Sell” rating by Chardan Capital Markets given on Monday, January 25. The stock of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has “Buy” rating given on Monday, September 7 by UBS. Canaccord Genuity maintained Regeneron Pharmaceuticals Inc (NASDAQ:REGN) rating on Friday, July 28. Canaccord Genuity has “Buy” rating and $52200 target. The company was initiated on Thursday, February 25 by Citigroup. The rating was initiated by Evercore with “Buy” on Wednesday, August 16.

Since March 29, 2017, it had 1 insider purchase, and 8 insider sales for $42.35 million activity. On Wednesday, June 14 the insider STAHL NEIL sold $4.01M. On Monday, June 12 BROWN MICHAEL S sold $948,890 worth of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) or 2,000 shares. Terifay Robert J sold $9.90 million worth of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) on Thursday, June 15. The insider VAGELOS P ROY sold 9,295 shares worth $4.26M. Sanofi bought 136,050 shares worth $65.06M. GOLDSTEIN JOSEPH L sold 1,000 shares worth $482,550.

Investors sentiment increased to 1.38 in Q4 2016. Its up 0.12, from 1.26 in 2016Q3. It improved, as 48 investors sold REGN shares while 151 reduced holdings. 60 funds opened positions while 188 raised stakes. 70.27 million shares or 1.15% less from 71.09 million shares in 2016Q3 were reported. Pitcairn Communications reported 1,980 shares. Cap Ww Investors reported 0.72% stake. Meiji Yasuda Asset Management Ltd reported 1,977 shares stake. Lazard Asset Limited Liability Company holds 4 shares or 0% of its portfolio. Ig Management Limited owns 5,600 shares. Creative Planning stated it has 0.04% of its portfolio in Regeneron Pharmaceuticals Inc (NASDAQ:REGN). Tradewinds Cap Llc has 0.02% invested in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) for 100 shares. Cubist Systematic Strategies Lc holds 0.06% or 1,971 shares in its portfolio. 4,015 were accumulated by Calamos Ltd Liability. Federated Investors Pa owns 154,371 shares for 0.17% of their portfolio. National Bank & Trust Of Nova Scotia reported 4,414 shares. Credit Suisse Ag reported 206,798 shares or 0.08% of all its holdings. Jnba Advsrs holds 22 shares or 0% of its portfolio. Cleararc Cap Inc invested in 1,845 shares. Gabelli Funds Limited Liability Com accumulated 6,000 shares.